For Healthcare Professionals: Clinical Updates in Lymphomas

Our specialists care for more than 1,200 individuals newly diagnosed with lymphoma each year, as well as many others receiving ongoing and follow-up care. A multidisciplinary team of physicians that includes medical and radiation oncologists and surgeons focuses its expertise on each case, personalizing care. Most patients with Hodgkin lymphoma have very good outcomes at our institution, and recent second-line treatment strategies have improved prospects for positive tumor response, reduced toxicity, and increased stem cell harvest for transplantation in patients with relapse. Recent data (2010) indicate a five-year cure rate of nearly 70 percent for patients following autologous transplant for relapsed Hodgkin lymphoma, compared to national averages of 45 to 50 percent as reported by the Bone Marrow Transplant Registry.

Our expertise in common as well as rare forms of non-Hodgkin lymphoma is similarly comprehensive, and we are pioneering advances in novel treatment approaches. A recent example is the introduction of a chemotherapy regimen that adds three new agents (ICE) to the standard R-CHOP formula to improve outcomes for high-risk patients with advanced and aggressive disease.

Predictor of Transplantation Failure in Relapsed and Refractory Follicular Lymphoma (2012 ASH Conference)

Fellow Matthew Lunning describes a retrospective study that examined event-free and overall survival among patients with relapsed/refractory follicular lymphoma.

Runtime: 03:00 minutes Published: 12/10/2012 - 1:11 PM
Phase I Clinical Trial of Anti-PD-1 in Hematologic Malignancy

Medical oncologist Alexander Lesokhin discusses a phase I dose escalation of an anti-PD-1 immunotherapy in patients with hematologic cancers.

Runtime: 03:00 minutes Published: 10/01/2012 - 8:42 AM
Clinical Trial: BMS-906024 for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Hematologist-oncologist Don Douer discusses a Phase I clinical trial of intravenous BMS-906024.

Runtime: 02:00 minutes Published: 05/01/2012 - 10:03 AM
Developing New Treatments for T Cell Lymphoma

Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.

Runtime: 05:00 minutes Published: 12/27/2011 - 10:48 AM
Role of FDG PET, CT, and Bone Marrow Biopsy (2011 ASH Conference)

Chief of the Lymphoma Service Andrew Zelenetz discusses a retrospective review examining the frequency of FDG avidity across a range of lymphoma histologies.

Runtime: 03:00 minutes Published: 12/10/2011 - 10:47 AM
Pegylated Liposomal Doxirubicin in Cutaneous T Cell Lymphoma (2011 ASH Conference)

Medical oncologist David Straus discusses how sequential bexarotene does not increase response rate in patients with Kaposi’s sarcoma.

Runtime: 02:00 minutes Published: 12/10/2011 - 10:42 AM
Allogeneic Transplant Following Brentuximab Vedotin Treatment (2011 ASH Conference)

Clinical Director of the Division of Hematologic Oncology Craig Moskowitz discusses positive responses of brentuximab vedotin in patients with Hodgkin lymphoma and systemic ALCL.

Runtime: 02:00 minutes Published: 12/10/2011 - 10:17 AM
Ofatumumab with ICE or DHAP Chemotherapy in B Cell Lymphoma (2011 ASH Conference)

Medical oncologist Matthew Matasar discusses the inclusion of OFA in second-line therapy for aggressive or relapsing B-cell non-Hodgkin’s lymphoma.

Runtime: 02:00 minutes Published: 12/10/2011 - 10:12 AM
Predicting Incidence of Dose Limiting Toxicities in Lymphoma Trials (2011 ASH Conference)

Clinical Director of the Lymphoma Outpatient Unit Paul Hamlin discusses relationship between DLT and SAE with increasing age and comorbidities in lymphoma trials.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:43 AM